Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SY-707
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Shouyao
Deal Size : Undisclosed
Deal Type : Collaboration
PharmaBlock Sciences Partners with Shouyao Holdings
Details : SY-707 is a new generation of highly active ALK/FAK/IGF1R multi-target kinase inhibitor independently developed by Shouyao. It is currently in a critical Phase II/III clinical study and has received conditional Phase II approval in China.
Brand Name : SY-707
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 03, 2021
Lead Product(s) : SY-707
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Shouyao
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : HQP1351
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Partnership
PharmaBlock Enters Strategic Partnership with Ascentage Pharma
Details : Ascentage's lead drug, HQP1351, is developed to treat drug-resistant chronic myeloid leukemia. PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two parties will continue to advance and expand CDMO cooperation for current and fu...
Brand Name : HQP1351
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : HQP1351
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
